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Despite improvements in prevention, diagnosis and 
treatment, Lyme borreliosis (LB) is still the most com-
mon arthropod-borne disease in temperate regions of 
the northern hemisphere, with risk of infection associ-
ated with occupation (e.g. forestry work) and certain 
outdoor recreational activities (e.g. mushroom collect-
ing). In Europe, LB is caused by infection with one or 
more pathogenic European genospecies of the spiro-
chaete Borrelia burgdorferi sensu lato, mainly trans-
mitted by the tick Ixodes ricinus. Recent surveys show 
that the overall prevalence of LB may be stabilising, 
but its geographical distribution is increasing. In addi-
tion, much remains to be discovered about the factors 
affecting genospecific prevalence, transmission and 
virulence, although avoidance of tick bite still appears 
to be the most efficient preventive measure. Uniform, 
European-wide surveillance programmes (particularly 
on a local scale) and standardisation of diagnostic 
tests and treatments are still urgently needed, espe-
cially in the light of climate change scenarios and 
land-use and socio-economic changes. Improved epi-
demiological knowledge will also aid development of 
more accurate risk prediction models for LB. Studies 
on the effects of biodiversity loss and ecosystem 
changes on LB emergence may identify new para-
digms for the prevention and control of LB and other 
tick-borne diseases.
Introduction
Lyme disease (or Lyme borreliosis, LB) is a multisys-
temic inflammatory disorder caused by an immune 
response to the pathogenic genomic species of Borrelia 
burgdorferi sensu lato (sl), which are transmitted by the 
hard ticks of the Ixodes ricinus species complex [1,2]. 
Despite substantial efforts to improve surveillance and 
control of LB in recent decades, it is still the most preva-
lent arthropod-borne disease in the temperate regions 
of the northern hemisphere [1], with approximately 
65,500 patients annually in Europe (including notified 
cases and qualified estimates per country from 1987 
to 2006, although the years covered vary) [3]. In the 
last few decades, the incidence of LB has been increas-
ing in some countries and areas of Europe, but not in 
others. However, the effect of improvements in diag-
nosis and reporting of the disease on such statistics 
is unknown (see [3] for a review). Less controversial is 
the fact that the geographical distribution of LB is still 
expanding, especially towards higher altitudes and 
latitudes ([3] and references therein). Moreover, LB is 
likely to become an increasingly relevant health risk in 
the near future due to complex interactions between 
diverse environmental and socio-economic factors, 
which will affect various aspects of disease ecology 
and epidemiology, as outlined below.
The importance of LB has led to a surge in research 
effort, on all aspects of LB biology, ecology and epi-
demiology. The purpose of this review is to summarise 
the most recent findings (especially those of the last 
five years) and indicate where there is still controversy 
and lack of knowledge.
Transmission, epidemiology 
and clinical symptoms
Ecology and disease transmission
The ecology of LB is based on interactions between the 
pathogenic agent (B. burgdorferi sl), the vector (Ixodes 
ticks) and vertebrate reservoir hosts.
The B. burgdorferi sl complex currently comprises at 
least 18 genospecies [2]. In Europe, several of these 
are pathogenic to humans: B. afzelii, B. garinii, B. burg-
dorferi sensu stricto (ss), B. bavariensis (previously B. 
garinii OspA serotype 4) and B. spielmanii, while the 
pathogenicity of others such as B. lusitaniae, B. valai-
siana, and B. bissetii is still uncertain [4]. In ticks, B. 
afzelii and B. garinii are the most common European 
circulating genospecies, followed by B. burgdorferi ss 
and B. valaisiana [5], whereas B. lusitaniae has a more 
focal distribution, especially in the Mediterranean 
basin [6]. Several genospecies may also be present 
simultaneously in a vector [5]. Although all pathogenic 
genospecies may cause erythema migrans (a red rash 
or patch on the skin), different genospecies are also 
associated with other clinical manifestations of the 
disease: B. burgdorferi ss is most often associated 
with arthritis and neuroborreliosis, B. garinii with neu-
roborreliosis, and B. afzelii with the chronic skin condi-
tion acrodermatitis chronica atrophicans [7].
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The distribution and prevalence of various genospecies 
is known to vary on a local and regional scale, both 
temporally and spatially [5,8] with a higher biodiversity 
of genospecies between 4 °W and 20 °E, where there is 
a higher prevalence of ticks infected with Borrelia [8]. 
In addition, there is an uneven geographical distribu-
tion of LB manifestations across Europe: in Norway, for 
example, 71% of LB cases have neuroborreliosis, while 
in Germany, 85% of cases have erythema migrans [9]. 
Borrelia genospecies are also associated with par-
ticular reservoir hosts: for example, B. afzelii and B. 
bavariensis tend to be associated with rodents, B. val-
aisiana and most B. garinii serotypes with birds [4], B. 
lusitaniae with lizards and B. spielmanii with dormice 
[10]. On the basis of the sequence of housekeeping 
genes, it has been shown that the genetic structuring 
of Borrelia genospecies is dependent on the migration 
pattern of host populations [11], so that genospecies 
that are associated with birds are dispersed further 
than those associated with mammals. Borrelia can also 
be classified according to outer surface protein (Osp) 
sequences (there are 21 OspC major groups) and recent 
research suggests that these genotypes are ecologi-
cally and epidemiologically diverse [12,13]. However, 
despite its relevance to development of preventive 
measures and treatment, knowledge of the distribution 
and symptoms associated with each genospecies and 
genotype is still far from complete, and the genetics of 
Borrelia transmission and virulence are starting to be 
unravelled [10,14].
The bridge vectors (vectors that feed on more than one 
host species) that transmit B. burgdorferi to humans 
in Europe are primarily the tick I. ricinus and, less fre-
quently, I. persulcatus. Ticks have three life stages: 
larva, nymph and adult, each lasting one to two years. 
Hard ticks seek hosts by ‘questing’ or climbing up 
grass stems or onto the edge of leaves, and extend-
ing their forelegs in response to thermal and chemical 
cues. They then drop or crawl onto hosts that pass or 
brush their forelegs. Larvae, nymphs and female adult 
ticks take one blood meal, lasting several days, from 
a vertebrate host (while adult males mate with feeding 
adult females). Between meals, the larvae and nymphs 
remain in leaf litter until moulting is complete, while 
adult females lay a batch of eggs in the litter then die). 
Borrelia may be acquired by a tick from feeding on an 
infected host or when feeding very close to an infected 
tick on the same, even uninfected, host (transmission 
by co-feeding) or from the site where an infected tick 
has recently finished its blood meal, (transmission 
by localised extended co-feeding) [10]. Once infected, 
competent tick species retain the pathogen even 
between moults, effectively transmitting the pathogen 
to the next feeding stage and/or to a host.
The most recent meta-analysis of surveillance data 
indicates that the overall mean prevalence of Borrelia 
infection in ticks in Europe is 13.7% (range: 0–49.1) 
although the prevalence is higher in adults (18.6%) 
than in nymphs (10.1%); Central Europe (Austria, Czech 
Republic , Germany, Switzerland, Slovenia and Slovakia) 
has by far the highest rates (in nymphs, >11%; in adults, 
>20%) [5]. In fact, peak prevalence has recently been 
confirmed between 5 °E and 25 °E longitude [8].
The capacity of ticks to transmit Borrelia to various hosts 
is influenced by a series of factors, including those intrin-
sic to ticks (e.g. questing behaviour, diapause duration, 
host preference, mating strategy [15] and tick density 
[16]), as well as extrinsic biotic and abiotic factors (e.g. 
climatic conditions, vegetation type and management, 
and host behaviour, abundance, susceptibility, tick 
burden and reservoir competence [17-20]). It has been 
shown that ticks infected with Borrelia may actually 
have an increased host-finding capability [21]. The tick–
host interaction is particularly important for Borrelia 
infection dynamics, since the feeding tick secretes sali-
vary vasoactive mediators and immunomodulators that 
facilitate the transmission of the pathogen from the tick 
to the host and vice versa [22]. Transmission efficiency 
can also vary in relation to Borrelia genospecies and 
duration of host infectivity [23,24].
Tick nymphs are mainly responsible for transmit-
ting Borrelia to humans and quest most actively from 
spring to autumn in microenvironments with more than 
85% relative humidity, such as in deciduous or mixed 
woodland with high ecotonal indices [17,25], as well as 
in suburban and urban environments [26] and road-
sides [27]. For humans, exposure risk in a known tick-
infested site can be as high as one infected tick per 
person per hour of exposure, or 0.25 infected ticks per 
100 metres walking distance [21]. Transmission does 
not usually occur within the first 24 hours of the blood 
meal [28], so immediate removal of ticks is a highly 
recommended preventive measure (see below).
In Europe, confirmed competent reservoir hosts (i.e. 
tick hosts that can be infected with Borrelia and trans-
mit this agent to uninfected ticks) include many com-
mon species of small and medium-sized rodent (mice, 
rats, squirrels, hares and rabbits), as well as several 
bird species (especially passerines), reptiles and 
insectivores [10,29]. Conversely, many large wild and 
domesticated vertebrates (e.g. deer and sheep) are 
considered non-competent reservoirs (i.e. ticks feed-
ing on them do not acquire Borrelia; however, ticks 
may transmit Borrelia to each other when feeding very 
close together on these non-competent hosts). Host 
specificity is the result of the resistance or sensitiv-
ity of Borrelia genospecies to the serum complement 
of various host species, which leads to the survival or 
death of the pathogen, respectively [30]. Importantly, 
non-competent reservoir hosts, such as deer, may also 
serve as crucial maintenance hosts for feeding ticks 
of all stages [10]. The presence and density of these 
hosts is associated with the density of ticks, but their 
effect on tick-borne infection dynamics is complex 
[31]. The presence of non-competent reservoir hosts 
can decrease the transmission potential of Borrelia, 
reducing the prevalence in the vector and subsequent 
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disease risk to humans (a dilution effect [32,33]). 
Ogden and Tsao [34] have shown that any host that 
feeds enough ticks to reduce the overall infection 
prevalence in nymphs, by diverting them away from 
competent host species, would be likely to increase 
the tick population density by improving the chances 
of successful tick feeding. However, the overall effects 
of changes in biodiversity on LB emergence have yet to 
be thoroughly investigated [35].
Epidemiology
Although LB is not a particularly new emerging dis-
ease, an accurate description of LB epidemiology in 
Europe is still not possible because few countries have 
made this disease mandatorily notifiable [3,9,36]. 
Unfortunately, there appears to be no plan to continu-
ously monitor LB at the European level [37]; instead 
this is recommended only ‘Where the epidemiological 
situation in a Member State so warrants ...’, although 
such situations are not defined [38]. Therefore, surveil-
lance statistics in Europe are based on non-standard-
ised case criteria and uncoordinated systems of data 
collection [39,40]. Moreover, these data are inaccurate 
because patients with erythema migrans and other 
clinically diagnosed cases may be under-reported, 
the geographical distribution of referrals for testing 
is unknown, the criteria for serological diagnoses are 
not standardised, seropositivity due to past infection 
may be included, and data from remote regions may be 
lacking [41,42]. In addition, patients may be infected 
by one or two (rarely three) pathogenic B. burgdorferi 
genospecies and heterogeneity in symptoms caused 
by these various agents complicates surveillance [43].
A summary of the currently available epidemiologi-
cal data is available in [3]. Epidemiological studies 
indicate the mean annual number of LB notified cases 
(including qualified estimates) in Europe is more than 
65,400 (incidence rates per country range from less 
than one per 100,000 population to about 350 per 
100,000 population). In Europe, LB occurs between 
35 °N and 60 °N, and generally below 1,300 metres 
above sea level. However, there is strong heterogene-
ity in spatial distribution: the level of antibodies to B. 
burgdorferi sl is highest in residents of northern and 
central countries and lowest in those in the southern 
countries. In addition, at a local level, there is a focal 
pattern of distribution related to suitable tick habitat, 
including some hotspots where more than 100 cases 
per 100,000 population per year are recorded (e.g. 
parts of Slovenia, Germany and Austria, the Baltic 
coastline of southern Sweden, and some Estonian and 
Finnish islands).
LB risk is specifically linked to tick abundance and 
exposure. Therefore, although higher risk is no longer 
considered to be correlated with residency in rural 
areas, higher LB risk is associated with occupation 
(e.g. forestry work and farming) and especially with 
certain leisure activities (e.g. hunting, mushroom col-
lecting and berry picking) and age (with two groups 
mainly affected: children aged 5–14 years and adults 
aged 50–64 years).
Since infection is correlated with tick abundance and 
exposure (and, therefore, tick activity), diagnosis of 
acute LB peaks in June and July in many northern and 
central countries of Europe, while a second smaller peak 
may occur in southern countries in late summer or early 
autumn; however, both erythema migrans and chronic 
forms of the disease can be diagnosed throughout the 
year [3]. Although the number of LB cases seems to be 
increasing in some areas, such trends are extremely 
heterogeneous and/or remain to be confirmed [3].
Clinical symptoms
The clinical presentation of LB ranges from acute to 
chronic illness, with wide variation attributed to the 
different Borrelia genospecies and/or genotypes impli-
cated in the infection (as described above and in [44]), 
although the exact mechanisms maintaining chronic 
symptoms have yet to be confirmed. Diagnosis is prima-
rily clinical and takes into account the risk of tick bite. 
Clinical case definitions for use in Europe – although not 
official European Union case definitions – are available 
in [45].
Briefly, several days or weeks after a tick bite, if 
Borrelia infection occurs, in 60–80% of cases this will 
be characterised by erythema migrans (the rash or 
patch on the skin about 10 cm across that may expand 
peripherally as a palpable band, and may or may not 
be itchy) [46], although early infection may be com-
pletely asymptomatic. Other early symptoms include 
influenza-like symptoms, fever, fatigue, headaches 
and muscle or joint pain. Several weeks or months 
after infection through a tick bite (with or without a 
previous history of erythema migrans), neuroborrelio-
sis (noted in 10–20% of symptomatic patients) in the 
form of meningoradiculitis, meningitis or meningoen-
cephalitis [47], Lyme arthritis or Borrelia lymphocytoma 
may occur [45]. Less frequently, multiple erythemata, 
or carditis are diagnosed [45,48]. Months or even 
years after Borrelia infection, acrodermatitis chronica 
atrophicans, lymphocytoma, chronic arthritis (fairly 
rare in Europe), encephalomyelitis or chronic neurobor-
reliosis (very rare in Europe) may be observed [45].
Microbial or serological confirmation of Borrelia infec-
tion is needed for all manifestations of the disease 
except for typical early skin lesions [49]. The diagnosis 
of some chronic forms of LB is currently controversial 
[50], and it has also been suggested that the overdiag-
nosis and overtreatment of LB may be an important 
problem [51].
Diagnostic methods
Direct detection of B. burgdorferi sl 
Although the diagnosis of LB is primarily based on the 
most obvious clinical sign, erythema migrans, diag-
nosis of other forms of LB require confirmation by 
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means of a diagnostic test [52]. A wide range of meth-
ods have been developed for the direct detection of B. 
burgdorferi sl in clinical tissue specimens, including 
microscopic examination, detection of B. burgdorferi-
specific proteins or nucleic acids, and cultivation. 
Although culture is the most commonly used method 
of direct detection, success rate depends on sample 
type. While mean recovery rates of Borrelia from skin 
biopsies of patients with erythema migrans and acro-
dermatitis chronica atrophicans are up to 70% [43], 
those for cerebrospinal fluid (CSF) are much lower. 
Future diagnostic methods may include PCR-based 
molecular techniques that can rapidly confirm clinical 
diagnosis of LB, and identify Borrelia genospecies in 
tissue specimens or cultured isolates [53]. However, 
even molecular methods have not yet been standard-
ised since protocols and gene targets vary between 
laboratories and more clinical validations are needed 
[53]. Importantly, a negative PCR result does not neces-
sarily indicate the absence of Borrelia [54]; therefore, 
the use of a PCR-based assay to confirm diagnosis of 
LB in the absence of serological evidence of Borrelia 
infection is not currently recommended.
Indirect diagnosis of B. burgdorferi sl
The complexity of the antigenic composition of B. burg-
dorferi sl and the temporal appearance of antibodies 
to different antigens at successive time intervals after 
Borrelia infection means the development of a sero-
logical test with high sensitivity and specificity is a 
challenge. The most commonly used serological meth-
ods for the detection of antibodies to B. burgdorferi 
sl include indirect immunofluorescent antibody assay 
(IFA) and an enzyme-linked immunosorbent assay 
(ELISA) [54]. Nevertheless, specific antibodies are 
often not detectable in the early stage of infection with 
the use of currently available test methods.
In more than 50% of cases, diagnosis of LB can be 
made on the basis of an expanding erythema (con-
firmed after a one-week follow-up). In the absence of 
erythema migrans at least one other clinical manifes-
tation must be noted and confirmed using serologi-
cal diagnosis of Borrelia in blood or CSF. According 
to the most recent German Society for Hygiene and 
Microbiology (Deutsche Gesellschaft für Hygiene und 
Mikrobiologie, DGHM) guidelines [43], serological 
diagnosis for patients in Europe should follow a two-
step procedure: (i) ELISA and if reactive, followed by (ii) 
an immunoblot, if possible using recombinant antigens 
(p100, p58, p41i, VlsE, OspC, DbpA), including those 
expressed primarily in vivo (VlsE and DbpA), instead 
of whole-cell lysate antigen blots. OspC and VlsE are 
the most sensitive antigens for IgM antibody detec-
tion [54]. European standardisation of these diagnostic 
tests and new markers for detecting active infections 
are urgently required [55]. 
Treatment
Surprisingly, our review found that there is no 
European consensus on treatment and that economic 
considerations and national guidelines on avoidance 
of drug resistance also impact the current treatment of 
choice (no comparative costs are available). Treatment 
of the vast majority of LB cases is based on antibiot-
ics, with drug type, dose, route (oral or intravenous) 
and duration varying with stage of the disease, as well 
as with symptoms. Treatment regimes and recommen-
dations are summarised from the regularly updated 
European Union Concerted Action on Lyme Borreliosis 
(EUCALB) website [1] and [49], where doses can also be 
found. See also [49,51,56] for recent reviews on evalu-
ation of treatments.
In general, in almost all LB cases, the disease is 
resolved with short courses of antibiotics [51,57], 
although longer courses are recommended for relapses 
or more serious and/or chronic forms. Some authors 
advocate that all symptomatic LB cases should be 
treated in order to avoid progression to later stages 
of the disease, and suggest that the earlier treatment 
begins, the less likely it is that more severe forms will 
follow [58]. However, overtreatment is considered a 
problem by others [51], although thus far, drug resist-
ance has been noted only in vitro [59]. On the other 
hand, few data are available on the risk of long-term 
effects of non-treatment in asymptomatic LB patients 
[60]. Several studies have now shown that a few so-
called chronic or ‘post-LB’ forms of the disease do not 
respond to antibiotics, although the reason for this is 
subject to some debate [50,51,61].
The main risks involved in treatment appear to be inap-
propriate patient management following inaccurate 
diagnosis. As mentioned above, both over- and under-
diagnosis of LB is suspected.
Prevention
It has been suggested that individual or community 
measures to reduce the probability of tick bites and LB 
infection could be extremely effective preventive meth-
ods [62-64]. For example, in order to decrease the risk 
of tick bites and Borrelia transmission, people living 
in or visiting tick-infested areas are advised to avoid 
tick habitats, to wear long, light-coloured trousers 
(tucking them into socks) and to use insect repellent 
that contains permethrin (on clothes) or N,N-Diethyl-
meta-toluamide (DEET) (on clothes or directly on skin). 
After visiting or working in such areas, a shower is rec-
ommended and a thorough check for ticks should be 
done, including careful inspection of the neck, arm-
pits and groin. Tick bites can also be avoided by care-
fully inspecting and removing ticks from pets [65]. Any 
attached ticks should be removed immediately with 
tweezers if available, by seizing and pulling steadily on 
the mouthparts, without twisting [66] and the attach-
ment site disinfected. Since ticks do not have a high 
probability of transmitting Borrelia until 12–24 hours 
after beginning to feed, immediate removal of ticks 
is one of the most effective ways of avoiding Borrelia 
infection. The site should be monitored for 30 days 
after the bite for signs of erythema migrans (there are 
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many websites that clearly illustrate these procedures, 
e.g. [67]).
There is currently no vaccine available on the European 
market. Thus far, the development of a vaccine for 
humans against B. burgdorferi sl infection has concen-
trated on the highly immunogenic outer surface pro-
teins of this pathogen. Although an OspA-based vaccine 
was developed and licensed in 1998, it was withdrawn 
from the market in 2002 for economic reasons, as well 
as doubts as to its long-term efficacy (it was also not 
recommended for children under the age of 15 years 
or for people with arthritis). The future of vaccines of 
this type is uncertain; vaccine research continues, with 
the aim of generating protection against all pathogenic 
genospecies of B. burgdorferi sl [68]. New approaches 
include transmission-blocking vaccines, which act on 
proteins produced by ticks that appear to improve the 
transmission of the Borrelia spirochaetes from vec-
tor to host [69]. Factors critical to an effective and 
accepted vaccine will probably include the following: 
a detailed knowledge of the host–parasite cycle on a 
local, regional and European scale and of the distribu-
tion and prevalence of Borrelia genospecies; a better 
understanding of the symptoms associated with infec-
tion with each genospecies; and standardised serolog-
ical confirmation of all suspected LB cases, including 
genospecies identification. Further studies on the role 
of surface lipoproteins of B. burgdorferi sl are also 
urgently needed [70]. In addition, enhancement of the 
epidemiological surveillance of LB, both of the disease 
itself and the abiotic and biotic factors that affect it, 
would improve risk assessment and aid prevention 
immeasureably [71].
Current geographical distribution of LB
LB occurs across Europe, with a distribution closely 
matching that of the vector I. ricinus. This tick spe-
cies can be infected with Borrelia throughout its wide 
latitudinal range, from northern Turkey and the Atlas 
Mountains of Tunisia to northern Sweden [8,72,73]. 
Infected tick density also decreases with increasing 
altitude, although the ticks are now found at up to 
1,300 metres [74,75]. Consequently, the incidence of LB 
decreases from the endemic areas of central Europe to 
the southern and northern limits [3,8]. However, stud-
ies on a local scale often reveal a higher incidence than 
previously recorded at a regional scale [16], so that 
monitoring LB locally may be important for treating and 
preventing the disease.
Factors triggering changes in LB incidence
The changes in capacity of I. ricinus to transmit B. 
burgdorferi sl in Europe could be due to changes in 
elements of the transmission process [40,76], such 
as: transmission coefficient (due to genetic changes 
in pathogen, vector and/or host [10]); survival rates of 
ticks (as a result of favourable abiotic changes [72]); 
increased tick abundance (resulting from increased 
availability of reservoir hosts and/or habitat [77]); 
increased exposure of humans to tick bites (due to an 
increase in outdoor activities [76]). Theoretical stud-
ies indicate that complex interactions between these 
factors will probably yield wide spatio-temporal fluc-
tuations in the relative abundance of different Borrelia 
genospecies and LB incidence [23].
Global climate change inducing higher minimum tem-
peratures (night-time and winter) and earlier springs 
are likely to affect many aspects of tick phenology [78], 
such as their local distribution, density and survival 
rates. For example, as a result of climate change, ticks 
have already spread into higher latitudes and altitudes 
in many European countries [72,75,78], while tick abun-
dance is mainly affected by host abundance and habitat 
structure [25,79]. Regional studies with reliable long-
term surveillance data show that an increase in tick 
abundance has also resulted in an increased incidence 
of LB, and that this increase is correlated with climatic 
factors [77]. However, climate change may not contrib-
ute to an overall increase in LB, since there may be an 
extended and more intense LB transmission season 
in some areas, while the risk of LB could decrease, at 
least temporarily, in locations with repeated droughts 
or severe floods, as shown in [80].
Instead, climate-related changes in land use and 
socio-economic influences on human behaviour are 
more likely to have a strong impact on the distribu-
tion and abundance of ticks and Borrelia infection risk 
(as noted for tick-borne encephalitis; [81]), especially 
in highly disturbed ecosystems, such as managed for-
ests, peri-agricultural and urban and peri-urban sites 
[79]. A concomitant increase in the density of wild 
and domestic vertebrates, paralleled with expansion 
of suitable habitats for competent reservoir hosts, is 
expected to increase tick density, B. burgdorferi cir-
culation and hence LB incidence [22,35,40,78,82]. The 
specific and combined contributions of all environmen-
tal and socio-economic factors to the observed pattern 
and predicted future impact of several tick-borne dis-
eases in Europe were assessed within the Framework 
6 Integrated Project Emerging Diseases in a changing 
European eNvironment (EDEN) [83].
Assessing the risk of infection
The complex multi-strain multi-host interactions 
associated with B. burgdorferi sl infection make it 
difficult to determine the risk of infection to humans 
[29,84,85]. While risk assessment may be based on 
well-planned surveillance of tick and Borrelia geno-
species distribution and abundance [86,87] and/or 
serological surveillance of Borrelia infection in humans 
[88-90], it has been also been suggested that high-
risk biotopes should be identified [91]. Spatial models 
have been developed to identify high-risk areas based 
on environmental and climatic features [92]. A model 
based on the long-term trends of habitat suitability for 
I. ricinus in Europe shows that the distribution of such 
habitats has remained relatively stable, although parts 
of Europe show increasing (Ireland, and parts of the 
United Kingdom, France, Spain, Portugal and Italy) or 
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a decreasing (Balkans, countries in the central parts of 
Europe and southern Scandinavia) suitability [80]. On 
a smaller spatio-temporal scale, the risk of exposure 
to Borrelia-infected ticks in the Italian Alps was pre-
dicted with a model based on bootstrap aggregation of 
tree-based classifiers within a geographic information 
system (GIS) [93]. The resulting map of the probability 
of encountering a questing I. ricinus nymph infected 
with B. burgdorferi sl has provided an important risk 
assessment tool for local human health authorities and 
policymakers.
Although the above methods can be used for risk and 
human exposure assessments, they cannot be used 
for addressing these as dynamic processes during a 
growing or declining epidemic. A detailed R0 (basic 
reproduction number) map would be an easy-to-inter-
pret overview of LB risk following the introduction of 
B. burgdorferi sl into an area and could be suitable for 
following an LB epidemic (R0 being a measure of the 
risk of establishment of a disease in a certain area or 
population, defined as the expected number of new 
infections induced by a typical infectious individual 
during the full infectious period in a susceptible popu-
lation [94]). For tick-borne pathogens, R0 can now be 
estimated using a next-generation matrix method [95], 
based on accurate biological conditions. However, 
Rosà and Pugliese [96] found that the effect of host 
densities on the R0 of tick-borne infections depends 
strongly on the regulation of tick populations. Since 
there is currently very little information on which fac-
tors affect natural tick populations, more complete, 
long-term field data are still needed before accurate R0 
maps can be produced.
Conclusion
In Europe, the annual number LB cases is increasing 
in some areas, and tick vectors are expanding their 
range, to higher altitudes and latitudes, suggesting 
that LB will remain an important health concern in the 
coming decades, especially in light of economic, land 
use and climate change predictions. In addition, the 
effect of the resulting biodiversity loss and ecosys-
tem changes on LB emergence should be an impor-
tant focus of investigation, especially to identify new 
paradigms for the prevention and control of LB and 
other tick-borne diseases. It emerges from our review 
that standardised diagnoses are crucial to treat-
ing and combatting LB in Europe, as are European-
wide reporting systems and datasets concerning all 
aspects of the molecular ecology and epidemiology 
of LB [10]. Preventive measures aimed at minimising 
tick-bite risk are promoted as one of the best ways 
to avoid Borrelia infection. Many authors agree that 
a concerted effort to improve surveillance is essen-
tial for monitoring this disease [9,36,49,55] and we 
consider that more complete eco-epidemiological 
knowledge is also needed to develop accurate risk 
prediction models.
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